Is Lithium Safe with Ketamine Therapy?

Lithium is one of the most clinically important medications in psychiatry and it's also one of the more interesting drugs to discuss in the context of at-home ketamine therapy. The pharmacology question itself is simple: there are no documented interaction concerns between lithium and ketamine, and the published evidence treats the combination as safe. The clinically interesting part is what lithium tells us about the patient: most lithium prescriptions are for bipolar disorder, and bipolar depression on ketamine carries a different conversation than unipolar depression on ketamine. This page works through both layers.

The pharmacology, briefly

Lithium is a mood stabilizer whose mechanism of action involves inositol depletion, glycogen synthase kinase 3 inhibition, and effects on multiple neurotransmitter systems including glutamate. Ketamine works on the NMDA glutamate receptor. The two drugs share a downstream interest in the glutamate pathway, which led to the theoretical hope that they might be synergistic in depression treatment.

The 2019 randomized controlled trial that directly tested this hypothesis (Costi and colleagues in Neuropsychopharmacology, N=42 patients with treatment-resistant unipolar depression who had responded to an initial ketamine infusion) randomized patients to lithium (600-1200 mg) or placebo during three additional ketamine sessions. The result was clean: no significant difference in MADRS depression scores between groups, and the combination was well tolerated. The systematic review of ketamine pharmacodynamic interactions (Veraart and colleagues 2021, International Journal of Neuropsychopharmacology) specifically reviewed lithium and reached the same conclusion: lithium did not seem to potentiate ketamine's antidepressant effect, and no special precautions are required when combining the two in depressed patients.

For our purposes that means two things. First, if you're already on lithium for an underlying indication, you continue it throughout your ketamine course. Second, no one should start lithium specifically to boost ketamine response, because the clinical evidence doesn't support that strategy.

Why "is lithium safe with ketamine?" is really a question about your diagnosis

Most patients aren't on lithium just because it's convenient. They're on lithium because one of three clinical pictures applies:

Unipolar treatment-resistant depression with lithium augmentation. Lithium augmentation of an antidepressant is one of the classic next steps for unipolar depression that hasn't responded to first-line treatment. Patients in this category often have major depressive disorder that has resisted multiple SSRIs and possibly SNRIs, and lithium has been added as an adjunct. These patients are textbook candidates for at-home ketamine, and the lithium itself is essentially a non-issue for the intake conversation.

Bipolar I or II depression. Lithium is the most evidence-based mood stabilizer for bipolar disorder and is the first-line agent for many patients. Bipolar depression on lithium is a more nuanced ketamine conversation because the underlying diagnosis (not the lithium itself) raises specific questions about manic switch risk, mood stability, and whether at-home is the appropriate setting.

Schizoaffective disorder. Patients with schizoaffective disorder on lithium are typically a more guarded conversation. We have a relationship with your treating psychiatrist as part of intake and the decision depends heavily on the stability and specifics of your current picture.

The verdict on the directory page is case-by-case because the answer differs across these three groups, not because the lithium + ketamine combination is itself complicated.

Unipolar TRD on lithium augmentation: straightforward

If you're on lithium because your psychiatrist added it to an antidepressant for treatment-resistant unipolar depression, your intake conversation looks like any other TRD patient's. We confirm:

Your recent lithium level (target 0.6-1.0 mEq/L for augmentation use, sometimes lower depending on your regimen) and that you have a level drawn within the past 6 months. If your last lab work is older than 6 months we ask for fresh draws before starting.

Your basic metabolic panel, especially creatinine and estimated GFR. Lithium is renally cleared and declining kidney function raises lithium levels, so confirming current renal function is good practice for any patient on lithium starting any new treatment.

Your existing psychiatrist or prescriber relationship. We coordinate at the level of "letting your prescriber know you're starting ketamine" rather than asking permission, but we want the channel open.

Once these are confirmed, you proceed with standard at-home ketamine onboarding. The lithium doesn't change the protocol, the dose, or the monitoring frequency.

Bipolar depression on lithium: the more detailed conversation

Bipolar depression treated with ketamine has been studied directly and the evidence is encouraging but more nuanced than for unipolar depression. The 2023 updated systematic review by Fancy and colleagues in Therapeutic Advances in Psychopharmacology synthesizes what the field knows.

Response rates are real: across pooled trial data, 48 percent of bipolar depression patients responded to ketamine (compared with 5 percent on placebo). Real-world data shows somewhat lower response rates (around 30 percent) than trial averages, consistent with the same pattern we see in unipolar depression studies.

The manic switch question, which is the headline clinical concern, has been studied carefully. Pooled across the major bipolar ketamine studies the manic or hypomanic switch rate is approximately 2 percent of patients treated. Important nuances on this number: switch events tend to occur late in treatment rather than acutely (one analysis put the median time from first treatment to switch event at 266 days, longer than the median treatment duration), and real-world studies of esketamine plus mood stabilizer specifically show no increased manic switch risk versus depression-only patients on equivalent treatment.

What this means practically: bipolar patients on lithium are not contraindicated for ketamine. The risk that exists is small and is meaningfully reduced by staying on the mood stabilizer. The 2015 study by Xu and colleagues (Journal of Affective Disorders) specifically tested ketamine in 36 patients with bipolar TRD maintained on lithium or valproate, found significant improvement in both groups, and reported no group differences between the two mood stabilizers.

The conversation we have at intake for bipolar patients:

We confirm the type of bipolar disorder (I, II, or schizoaffective with bipolar features). Bipolar I patients tend to get a more detailed conversation about closer monitoring, particularly for the first few sessions.

We review your most recent mood-episode history, ideally within the past 12 months. Recent manic, hypomanic, or mixed episodes are a flag for closer monitoring rather than an automatic contraindication.

We confirm current mood stability and your relationship with your treating psychiatrist. For most bipolar patients we coordinate with the existing psychiatrist rather than replacing that care.

For some bipolar I patients with a more complicated picture we recommend a closer-monitored setting (in-office or clinic) for the loading phase, with a possible step-down to at-home once we see how you respond. This isn't because at-home is unsafe in general; it's because the combination of bipolar I with treatment-resistant depression in someone we haven't met before warrants closer eyes during the first few sessions.

Renal function and lithium level: the standard intake check

Independent of ketamine, lithium prescribing standards require ongoing monitoring of renal function and blood lithium level. Lithium has a narrow therapeutic index (target 0.6-1.2 mEq/L for maintenance), is essentially renally cleared, and several common medications (NSAIDs, ACE inhibitors, ARBs, thiazide diuretics) can raise lithium levels and push patients into toxicity range.

When we intake a patient on lithium for ketamine therapy, we ask for:

A recent lithium level drawn within the past 6 months. Older than that, we ask for a fresh draw. If your level is at the upper end of the therapeutic range or has been trending up, we may ask for a current level before starting.

A basic metabolic panel including sodium, creatinine, and eGFR within the past 6 months. Renal function changes matter more than any specific ketamine consideration, but it's part of safe lithium prescribing.

A medication reconciliation specifically checking for NSAIDs (including over-the-counter ibuprofen and naproxen), ACE inhibitors, ARBs, and thiazide diuretics. If you're on any of these alongside lithium, we want to confirm your psychiatrist is monitoring; the issue is the lithium interaction with those drugs, not with ketamine, but it affects safe ongoing prescribing.

A history of any past lithium toxicity events. A remote history of mild toxicity (during a dehydration episode, an NSAID flare) doesn't change anything; a more recent significant toxicity event opens a conversation about whether the lithium dose itself is the right level.

These are all routine for any prescriber managing a patient on lithium. We do them at intake to confirm the picture, not as additional restrictions specific to ketamine.

What we do at intake at Tovani

When a patient on lithium contacts Tovani for ketamine evaluation, the intake process layers three confirmations on top of standard eligibility screening:

The indication for lithium (unipolar TRD augmentation vs. bipolar I vs. bipolar II vs. schizoaffective).

Recent lithium level and basic metabolic panel within 6 months, with a fresh draw requested if older.

Mood stability across the past 6-12 months, with explicit attention to manic, hypomanic, or mixed episodes.

For unipolar TRD on lithium augmentation: standard at-home onboarding, no protocol changes.

For bipolar II depression on lithium: usually standard at-home onboarding, sometimes with more frequent check-ins during loading. Continuing lithium throughout is the default.

For bipolar I depression on lithium: a more detailed conversation. We often coordinate with the existing psychiatrist and may recommend a closer-monitored setting initially, with potential step-down to at-home.

For schizoaffective disorder: even more individualized, with active coordination of care.

Bottom line

Lithium and ketamine combine safely with no documented pharmacologic interaction. The case-by-case nature of the verdict reflects what lithium says about your underlying clinical picture, not the drug combination itself. Patients on lithium for unipolar TRD augmentation are routine candidates for at-home ketamine with an intake review of recent labs. Patients on lithium for bipolar disorder have a more detailed conversation about manic switch risk (small but real, around 2 percent, meaningfully lower when the mood stabilizer is continued), about setting (at-home vs. closer monitoring), and about coordination with their existing psychiatrist. The lithium itself is a non-issue; staying on it during the ketamine course is the right call.